|  |  |
| --- | --- |
|  | |
| Journal Name: | [**Asian Journal of Research in Medical and Pharmaceutical Sciences**](https://journalajrimps.com/index.php/AJRIMPS) |
| Manuscript Number: | **Ms\_AJRIMPS\_137315** |
| Title of the Manuscript: | **Communication Technologies: Bridging Gaps in Pharmaceutical Industry Connectivity** |
| Type of the Article |  |

|  |  |  |
| --- | --- | --- |
| PART 1: Comments | | |
|  | Reviewer’s comment Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review. | **Author’s Feedback** (It is mandatory that authors should write his/her feedback here) |
| **Please write a few sentences regarding the importance of**  **this manuscript for the scientific community.**  **A minimum of 3-4 sentences may be required**  **for this part.** | This manuscript is extremely important to the scientific community for its timely and comprehensive contribution on how EHRs, AI, telemedicine, blockchain, and other emerging communication technologies, are reshaping connectivity in connection with the pharmaceutical industry. The article acknowledges persistent challenges in the industry, from data silos and interoperability to regulatory fragmentation, and provides practicable frameworks and evidence-based solutions that are highly relevant to the digital evolution of healthcare. Multidisciplinary and cross-faculty approaches that incorporate technical, regulatory and clinical aspects of recommendations are beneficial for academic researchers, healthcare professionals, policy makers, and pharmaceutical stakeholders. The interoperability framework (in particular the combination of FHIR and AI) offers practicable recommendations to follow that could help improve the efficiency of drug development and patient safety. |  |
| **Is the title of the article suitable?**  **(If not please suggest an alternative title)** | Yes, because it’s generally clear and aligns with the manuscript’s core themes. |  |
| Is the abstract of the articlecomprehensive? Do you suggest theaddition (or deletion) of some points in thissection? Please write your suggestions here. | The abstract is comprehensive and covers all the research. However, he are my few suggestions to improved for clarity and focus:   1. Clarify the scope: Mention the methodology e.g., review + framework proposal. 2. Refine key findings: Be specific about the FHIR + AI outcome e.g., reduction in data silos, improved efficiency. 3. Repetition: The phrase “this study” appears redundantly. 4. Suggestion: End with a strong concluding sentence that highlight the manuscript’s contribution to pharmaceutical digital transformation.   The abstract is comprehensive and covers all aspects of the research. However, I have my few suggestions for clarity and focus:  I. Clarify the scope: State the methodology e.g., review + framework proposal  II. Refine key findings: Be specific about FHIR + AI finding i.e., reduction in data silos, efficiency.  III. Identify repetition: “this study” said many times  IV. Suggestion: Finish with a concluding statement, making a statement about the manuscript to the impact of the digital transformation in pharmaceutical. |  |
| Is the manuscript scientifically, correct?Please write here. | Yes, the manuscript is largely scientifically correct. It presents up-to-date references, accurate use of technical terms, and integrates evidence-based findings from credible sources. The use of real-world datasets e.g., Epic, Cerner, pilot studies, and metrics strengthens its validity.  Yes, the reference is largely correct scientifically. It includes up-to-date references, appropriately uses appropriate technical terminology, and incorporates evidence-informed findings from appropriate and the highest quality evidence-informed research. The inclusion of real-world datasets (e.g., Epic, Cerner, pilot studies, and various metrics) serves to strengthen the overall validity of the study. |  |
| **Are the references sufficient and recent? If you have**  **suggestions of additional references, please mention**  **them in the review form.** | Yes, the references are mostly appropriate, relevant, and timely (2020-2024), which speaks to the scientific validity of the manuscript. The references include, reputable peer-reviewed journals, official reports (FDA, WHO), and industry studies.  Suggestion: You could consider adding references that explore interoperability from Journal of Biomedical Informatics or JMIR Medical Informatics for further scholarly scope. For example: Mandl, K. D., & Kohane, I. S. (2016). Time for a patient-driven health information economy? New England Journal of Medicine, 374(3), 205-208. https://doi.org/10.1056/NEJMp1513944 |  |
| Is the language/English quality of the articlesuitable for scholarly communications? | After reviewing this text, the language is generally appropriate for scholarly communication, but there are opportunities to improve the language/English quality. issues with English within the document. Below you will find some examples - with page numbers - stating some potential for language/English quality improvement.  Page 1 (Abstract):  - Change "ERHs" to "EHRs" for each instance. This assumes that EHR is the appropriate acronym for "Electronic Health Record".  - (“This study concludes FHIR + AIs potential…”) Consider revising to: “This study concludes that FHIR + AI has the potential…”  Page 2 (Introduction):  - This part of the text was not very clear as written: - "... in the communications of the pharma sector." A more satisfactory rewrite may be: - "... in communication of the pharma sector.”  Page 8 (Problem Statement):  - The wording of "invincible data silos" was used but most likely intended the wording of "invisible data silos" or "intractable data silos". |  |
| Optional/General comments | This paper discusses a topic with significant relevance, with applicability for the use of digital transformation in the pharmaceutical industry. The interdisciplinary combination of AI, blockchain, FHIR, and big data will help in industry and academia gain an important understanding of the topic. |  |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | **Reviewer’s comment** | **Author’s Feedback** (It is mandatory that authors should write his/her feedback here) |
| **Are there ethical issues in this manuscript?** | *(If yes, Kindly please write down the ethical issues here in details)* |  |

**Reviewer details:**

**Damilola Osamika, Bowling Green State University, United States of America**